Eli Lilly and Co LLY:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 12:06 PM EDT

774.68

-3.09 (-0.40%)

Volume

613,760

52 week range

419.80 - 800.78

Open779.10
Day High779.95
Day Low772.20
Prev Close777.77
52 Week High800.78
52 Week High Date03/04/24
52 Week Low419.80
52 Week Low Date05/25/23

Key Stats

Market Cap736.26B
Shares Out950.41M
10 Day Average Volume3.38M
Dividend5.20
Dividend Yield0.67%
Beta0.36
YTD % Change32.91

KEY STATS

Open779.10
Day High779.95
Day Low772.20
Prev Close777.77
52 Week High800.78
52 Week High Date03/04/24
52 Week Low419.80
52 Week Low Date05/25/23
Market Cap736.26B
Shares Out950.41M
10 Day Average Volume3.38M
Dividend5.20
Dividend Yield0.67%
Beta0.36
YTD % Change32.91

RATIOS/PROFITABILITY

EPS (TTM)6.79
P/E (TTM)114.03
Fwd P/E (NTM)56.72
EBITDA (TTM)12.912B
ROE (TTM)51.15%
Revenue (TTM)35.932B
Gross Margin (TTM)80.16%
Net Margin (TTM)17.08%
Debt To Equity (MRQ)204.58%

EVENTS

Earnings Date08/08/2024(est)
Ex Div Date05/15/2024
Div Amount1.30
Split Date-
Split Factor-

Latest On Eli Lilly and Co

Healthy Returns: Eli Lilly, Novo Nordisk are boosting weight loss drug supply 21 Hours AgoCNBC.com
New rivals could threaten Novo Nordisk, Eli Lilly's weight loss drug dominance May 7, 2024CNBC.com
What's driving this multiday rally, plus Jim Cramer's quick takes on 4 stocksMay 6, 2024CNBC.com
Generative AI will be designing new drugs all on its own in the near futureMay 5, 2024CNBC.com
Earnings will drive the market next week — what we expect from 2 portfolio stocksMay 4, 2024CNBC.com

Content From Our Affiliates

Lilly Declares Second-Quarter 2024 DividendMay 6, 2024TipRanks
Barclays Remains a Buy on Eli Lilly & Co (LLY)May 6, 2024TipRanks
Amgen price target raised to $325 from $315 at BofAMay 3, 2024TipRanks
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Eli Lilly & Co (LLY)May 2, 2024TipRanks
Eli Lilly price target raised to $892 from $850 at TruistMay 1, 2024TipRanks

Profile

Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz....

David Ricks

Chairman of the Board, President, Chief Executive Officer

Anat Ashkenazi

Chief Financial Officer, Executive Vice President

Diogo Rau

Executive Vice President, Chief Information and Digital Officer

Patrik Jonsson

Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USA

Alonzo Weems

Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer

Address

Lilly Corporate Ctr

Drop Code 1094, Lilly Corporate Ctr

Indianapolis, IN

46285-0001

United States

https://www.lilly.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
MRK Merck & Co Inc	129.69	-0.69	-0.53%
ABBV AbbVie Inc	160.08	-2.47	-1.52%
JNJ Johnson & Johnson	149.07	+0.35	+0.24%
AZN AstraZeneca PLC	76.86	+0.54	+0.71%
NVS Novartis AG	99.64	+0.57	+0.58%